BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 10518193)

  • 1. Enhanced cytotoxic interaction between 5-fluorouracil and 4-hydroperoxycyclophosphamide against L1210 murine leukemic cells: applicability to ex vivo purging.
    Mao XY; Higashigawa M; M'Soka T; Shimono Y; Nagata T; Inamochi H; Cao DC; Hori H; Kawasaki H; Sakurai M
    Cancer Invest; 1999; 17(7):486-93. PubMed ID: 10518193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combinations of 4-hydroperoxycyclophosphamide (4-HC) and cisplatin for bone marrow purging in autologous marrow transplantation: an update.
    Peters RH; Brandon CS; Avila LA; Gale GR; Stuart RK
    Prog Clin Biol Res; 1990; 333():57-68. PubMed ID: 2309001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Purging in autologous hematopoietic stem cell transplantation using adenosine triphosphate (ATP) and 4-hydroperoxycyclophosphamide (4-HC).
    Hatta Y; Itoh T; Baba M; Miyajima T; Shimojima H; Sawada U; Horie T
    Leuk Res; 2002 May; 26(5):477-82. PubMed ID: 11916522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic effect of 4-hydroperoxycyclophosphamide and etoposide on a human promyelocytic leukemia cell line (HL-60) demonstrated by computer analysis.
    Chang TT; Gulati SC; Chou TC; Vega R; Gandola L; Ibrahim SM; Yopp J; Colvin M; Clarkson BD
    Cancer Res; 1985 Jun; 45(6):2434-9. PubMed ID: 3857119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Goralatide (AcSDKP) selectively protects murine hematopoietic progenitors and stem cells against hyperthermic damage.
    Wierenga PK; Konings AW
    Exp Hematol; 1996 Feb; 24(2):246-52. PubMed ID: 8641348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of the ability to purge tumor from murine bone marrow using clonogenic assays.
    Jones RJ; Colvin OM; Sensenbrenner LL
    Cancer Res; 1988 Jun; 48(12):3394-7. PubMed ID: 3285994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Schedule-dependent antitumor activity and toxicity of combinations of 5-fluorouracil and cisplatin/carboplatin against L1210 leukemia-bearing mice.
    Fujimoto S
    Biol Pharm Bull; 2006 Nov; 29(11):2260-6. PubMed ID: 17077525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial.
    Shpall EJ; Jones RB; Bast RC; Rosner GL; Vandermark R; Ross M; Affronti ML; Johnston C; Eggleston S; Tepperburg M
    J Clin Oncol; 1991 Jan; 9(1):85-93. PubMed ID: 1985173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the protection of murine bone marrow stem cells by WR-2721 during in vitro treatment with mafosfamide.
    Jiang R; Bony V; Lopez M
    Prog Clin Biol Res; 1994; 389():23-9. PubMed ID: 7700906
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of combined treatment with interleukin-3 and interleukin-6 on 4-hydroperoxycyclophosphamide-mediated reduction of glutathione levels and cytotoxicity in normal and leukemic bone marrow progenitor cells.
    Bhalla K; Bullock G; Lutzky J; Holladay C; Ibrado AM; Jasiok M; Singh S
    Leukemia; 1992 Aug; 6(8):814-9. PubMed ID: 1640734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of ex vivo purging for autologous bone marrow transplantation in the treatment of acute nonlymphoblastic leukemia.
    Rowley SD; Jones RJ; Piantadosi S; Braine HG; Colvin OM; Davis J; Saral R; Sharkis S; Wingard J; Yeager AM
    Blood; 1989 Jul; 74(1):501-6. PubMed ID: 2665843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ex vivo expansion of normal progenitor cells from acute myeloid leukemia cell-contaminated CD34+ peripheral blood progenitor cells after mafosfamide purging.
    Stilz R; Grünebach F; Bader P; Vogel W; Kanz L; Brugger W; Scheding S
    J Hematother Stem Cell Res; 2001 Dec; 10(6):777-85. PubMed ID: 11798504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New strategies in marrow purging for breast cancer patients receiving high-dose chemotherapy with autologous bone marrow transplantation.
    Shpall EJ; Stemmer SM; Bearman SI; Myers S; Purdy M; Jones RB
    Breast Cancer Res Treat; 1993; 26 Suppl():S19-23. PubMed ID: 7691269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination chemotherapy with a new folate analog: activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models.
    Schmid FA; Sirotnak FM; Otter GM; DeGraw JI
    Cancer Treat Rep; 1987; 71(7-8):727-32. PubMed ID: 3607784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of combination drug purging for autologous bone marrow transplantation.
    Rowley SD; Miller CB; Piantadosi S; Davis JM; Santos GW; Jones RJ
    J Clin Oncol; 1991 Dec; 9(12):2210-8. PubMed ID: 1960561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of benzoporphyrin derivative, a photosensitizer, in selective destruction of leukemia cells using a murine tumor model.
    Jamieson C; Richter A; Levy JG
    Exp Hematol; 1993 May; 21(5):629-34. PubMed ID: 8513863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TGF-beta 3 protects normal human hematopoietic progenitor cells treated with 4-hydroperoxycyclophosphamide in vitro.
    Lemoli RM; Strife A; Clarkson BD; Haley JD; Gulati SC
    Exp Hematol; 1992 Dec; 20(11):1252-6. PubMed ID: 1493854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro sensitivity of human hematopoietic progenitor cells to 4-hydroperoxycyclophosphamide.
    Ratajczak MZ; Ratajczak J; Kuczynski W; Light B; Lusk EJ; Gewirtz AM
    Exp Hematol; 1993 Dec; 21(13):1663-7. PubMed ID: 8243568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic effects of Actinobacillus suis cells in combination with 5-fluorouracil on mice bearing murine L1210 leukemia cells.
    Watanabe T; Itoh S
    Cancer Immunol Immunother; 1997 Jun; 44(4):216-20. PubMed ID: 9222280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support.
    Shpall EJ; Stemmer SM; Hami L; Franklin WA; Shaw L; Bonner HS; Bearman SI; Peters WP; Bast RC; McCulloch W
    Blood; 1994 Jun; 83(11):3132-7. PubMed ID: 8193351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.